Article Text

Download PDFPDF

Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection
Free
  1. D W Evans1,
  2. S L Hosking2,
  3. D Gherghel2,
  4. J D Bartlett3
  1. 1School of Optometry, University of Alabama at Birmingham, Birmingham, AL, USA
  2. 2Neuroscience Research Institute, Aston University, Aston Triangle, Birmingham B4 7ET, UK
  3. 3School of Optometry, University of Alabama at Birmingham, and Department of Pharmacology and Toxicology, School of Medicine, University of Alabama, Birmingham, AL, USA
  1. Correspondence to: Sarah L Hosking Neuroscience Research Institute, Aston University, Aston Triangle, Birmingham B4 7ET, UK; s.l.hoskingaston.ac.uk

Abstract

Aims: To determine the visual outcome following initiation of brimonidine therapy in glaucoma.

Methods: 16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months.

Results: IOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p = 0.043, p = 0.017); in the left eye at 3 and 12 cpd (p = 0.044, p = 0.046). Timolol reduced CS at 18 cpd in the right eye (p = 0.041). There was no change in any other measured parameters.

Conclusion: Glaucoma patients exhibit improved CS on initiation of brimonidine therapy.

  • primary open angle glaucoma
  • brimonidine
  • timolol
  • contrast sensitivity
  • neuroprotection
View Full Text

Statistics from Altmetric.com

Footnotes

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.